TOBRASONE Trademark

Trademark Overview

On Friday, February 15, 2019, a trademark application was filed for TOBRASONE with the United States Patent and Trademark Office. The USPTO has given the TOBRASONE trademark a serial number of 88304021. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, October 3, 2022. This trademark is owned by EYEVANCE PHARMACEUTICALS LLC. The TOBRASONE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical products for ophthalmological use
tobrasone

General Information

Serial Number88304021
Word MarkTOBRASONE
Filing DateFriday, February 15, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, October 3, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 2, 2019

Trademark Statements

Goods and ServicesPharmaceutical products for ophthalmological use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, March 9, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameEYEVANCE PHARMACEUTICALS LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressFort Worth, TX 76102
Party NameEYEVANCE PHARMACEUTICALS LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressFort Worth, TX 76102

Trademark Events

Event DateEvent Description
Monday, October 3, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, October 3, 2022ABANDONMENT - NO USE STATEMENT FILED
Wednesday, March 2, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, March 1, 2022SOU EXTENSION 5 GRANTED
Tuesday, February 22, 2022SOU EXTENSION 5 FILED
Tuesday, March 1, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, February 22, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, August 17, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, August 13, 2021SOU EXTENSION 4 GRANTED
Friday, August 13, 2021SOU EXTENSION 4 FILED
Friday, August 13, 2021SOU TEAS EXTENSION RECEIVED
Wednesday, February 3, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, February 1, 2021SOU EXTENSION 3 GRANTED
Monday, February 1, 2021SOU EXTENSION 3 FILED
Monday, February 1, 2021SOU TEAS EXTENSION RECEIVED
Friday, August 21, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 19, 2020SOU EXTENSION 2 GRANTED
Wednesday, August 19, 2020SOU EXTENSION 2 FILED
Wednesday, August 19, 2020SOU TEAS EXTENSION RECEIVED
Tuesday, February 18, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, February 14, 2020SOU EXTENSION 1 GRANTED
Friday, February 14, 2020SOU EXTENSION 1 FILED
Friday, February 14, 2020SOU TEAS EXTENSION RECEIVED
Tuesday, August 27, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 2, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 2, 2019PUBLISHED FOR OPPOSITION
Wednesday, June 12, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, May 29, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, May 25, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Saturday, May 25, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, May 23, 2019ASSIGNED TO LIE
Thursday, May 16, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, April 29, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, April 29, 2019NON-FINAL ACTION E-MAILED
Monday, April 29, 2019NON-FINAL ACTION WRITTEN
Saturday, April 27, 2019ASSIGNED TO EXAMINER
Saturday, March 9, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, February 19, 2019NEW APPLICATION ENTERED

Related Keywords

tobrasone ophthalmological products pharmaceutical